Fig. 2: MRPL13 promotes malignant progression of OC cells in vitro and in vivo. | Cell Death & Disease

Fig. 2: MRPL13 promotes malignant progression of OC cells in vitro and in vivo.

From: MRPL13 enhances mitochondrial function and promotes tumor progression in ovarian cancer by inhibiting mPTP opening via SLC25A6

Fig. 2

A CCK-8 assays were utilized to evaluate the cell viability in OVCAR-3 and ES-2 cells with MRPL13 knockdown. *: siControl vs siMRPL13. B EdU assays were conducted to assess cell proliferation in OVCAR-3 and ES-2 cells with MRPL13 knockdown. DAPI (blue) staining was performed to indicate total cells, while EdU (red) incorporation indicated cells with active DNA replication. C Transwell assays were conducted to assess cell invasion ability in OVCAR-3 and ES-2 cells with MRPL13 knockdown. D Wound healing assays were used to evaluate cell migration ability in OVCAR-3 and ES-2 cells with MRPL13 knockdown. E Cell apoptosis of OVCAR-3 and ES-2 cells in the MRPL13 knockdown groups was validated by flow cytometry. F Protein expression level of PCNA, Bcl-2, Bax, Caspase-3 and Cleaved Caspase-3 were monitored by western blot for lysates from OVCAR-3 and ES-2 cells with MRPL13 knockdown. β-Actin was used as an internal control. All assays were performed in three independent experiments. G Subcutaneous xenograft tumor model of OC was established in BALB/c nude mice with MRPL13 stable overexpression ES-2 cells. H The weights of subcutaneous xenograft tumors were measured after euthanized. I Tumor volumes were measured at three-day intervals following the subcutaneous injection to generate tumor growth curve. J Representative images of Hematoxylin-eosin (H&E) staining and IHC staining on the paraffin sections of xenograft tumors to visualize the expression of Ki-67 and MRPL13. Scale bar, 100 μm (×200, upper) and 50 μm (×400, lower). Data are presented as mean ± SD. **, P < 0.01; ***, P < 0.001.

Back to article page